2
|
Crocchiolo R, Fallanca F, Giovacchini G, Ferreri AJM, Assanelli A, Verona C, Pescarollo A, Bregni M, Ponzoni M, Gianolli L, Fazio F, Ciceri F. Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma. Ann Hematol 2009; 88:1229-36. [PMID: 19468730 DOI: 10.1007/s00277-009-0752-4] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2009] [Accepted: 04/30/2009] [Indexed: 12/16/2022]
Abstract
The role of 18FDG-PET/CT during follow-up of patients affected by Hodgkin's lymphoma (HL) in complete remission after treatment is not fully elucidated, since a wide use of 18F fluorodeoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT) in this setting could be limited by a relative high rate of false-positive results. Herein, we summarize a retrospective analysis of 27 patients with Hodgkin's lymphoma in complete remission after the first-line (n = 20) or salvage (n = 7) therapy receiving serial 18FDG-PET/CT scans during follow-up. Out of 165 scans, 13 were suspected for relapse, which was confirmed in seven patients. All relapses were correctly identified by 18FDG-PET/CT positivity, with a 100% sensitivity; false-positive rate was 46% and negative predictive value was 100%. True-positive findings were mostly associated with multiple sites, subdiaphragmatic involvement, and/or previous sites of disease. According to our results, we conclude that performing routine PET/CT scan during follow-up of those patients who are at high risk of relapse would be advisable, although caution must be adopted when interpreting PET/CT results due to the relatively high rate of false-positive findings. If FDG abnormal uptake is present at multiple nodal sites, subdiaphragmatic lymph nodes, or previous sites of disease, histological verification of PET abnormal findings is warranted.
Collapse
Affiliation(s)
- R Crocchiolo
- Hematology and BMT Unit, San Raffaele Scientific Institute, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Bregni M, Bernardi M, Servida P, Pescarollo A, Crocchiolo R, Treppiedi E, Corradini P, Ciceri F, Peccatori J. Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7037 Background: Stem cell transplantation from a HLA-compatible sibling donor is an adoptive immunotherapy for cytokine-refractory, metastatic clear-cell renal cell cancer (RCC). However, the recent introduction of targeted therapy compounds has reduced the interest in this therapeutic strategy. We have reanalyzed our series with the aim to assess long-term benefit from allografting. Methods: Twenty-five RCC patients (Table) received a reduced-intensity allograft from an HLA-identical sibling donor after a thiotepa, fludarabine, and cyclophosphamide conditioning regimen, and a cyclosporine-based GVHD prophylaxis. Allogeneic peripheral blood hematopoietic cells were collected by apheresis after filgrastim treatment of the donor. Results: Best response to allograft was evaluable in 24 patients: 1 complete remission, 4 partial remissions, 12 minor response or stable disease, 7 progressive disease. Six patients died because of transplant related mortality (TRM) at day +12, +71, +86, +151, +259, +478. Cause of death was infection in four cases, GVHD in one case, and acute renal failure in one case. Fourteen patients died for progressive disease at median 415 (36–958) days from transplant. One-year survival was 48%, and 5-yr survival was 20%. At a median observation time of 65 months, 5 patients are alive, one in CR, one in PR, and three with stable disease. At multivariate analysis, CRP value before transplant, number of CD34+ infused cells and disease status at +90 significantly correlated with survival. Survival of patients at favourable/intermediate-risk according to the MSKCC score that underwent allografting was better in comparison to the survival predicted by historical controls. Conclusions: Transplantation is able to induce long-term disease control in a fraction (20%) of relapsed RCC patients. Identifying patients who could benefit from allografting, and incorporating molecularly targeted drugs in the transplant regimen, could further decrease progression and prolong overall survival. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Bregni
- Ospedale San Giuseppe, Milano, Italy; Istituto Scientifico San Raffaele, Milano, Italy; Istituto Oncologico Svizzera Italiana, Bellinzona, Switzerland; Ospedale Evangelico, Genova, Italy; Istituto Nazionale Tumori, Milano, Italy
| | - M. Bernardi
- Ospedale San Giuseppe, Milano, Italy; Istituto Scientifico San Raffaele, Milano, Italy; Istituto Oncologico Svizzera Italiana, Bellinzona, Switzerland; Ospedale Evangelico, Genova, Italy; Istituto Nazionale Tumori, Milano, Italy
| | - P. Servida
- Ospedale San Giuseppe, Milano, Italy; Istituto Scientifico San Raffaele, Milano, Italy; Istituto Oncologico Svizzera Italiana, Bellinzona, Switzerland; Ospedale Evangelico, Genova, Italy; Istituto Nazionale Tumori, Milano, Italy
| | - A. Pescarollo
- Ospedale San Giuseppe, Milano, Italy; Istituto Scientifico San Raffaele, Milano, Italy; Istituto Oncologico Svizzera Italiana, Bellinzona, Switzerland; Ospedale Evangelico, Genova, Italy; Istituto Nazionale Tumori, Milano, Italy
| | - R. Crocchiolo
- Ospedale San Giuseppe, Milano, Italy; Istituto Scientifico San Raffaele, Milano, Italy; Istituto Oncologico Svizzera Italiana, Bellinzona, Switzerland; Ospedale Evangelico, Genova, Italy; Istituto Nazionale Tumori, Milano, Italy
| | - E. Treppiedi
- Ospedale San Giuseppe, Milano, Italy; Istituto Scientifico San Raffaele, Milano, Italy; Istituto Oncologico Svizzera Italiana, Bellinzona, Switzerland; Ospedale Evangelico, Genova, Italy; Istituto Nazionale Tumori, Milano, Italy
| | - P. Corradini
- Ospedale San Giuseppe, Milano, Italy; Istituto Scientifico San Raffaele, Milano, Italy; Istituto Oncologico Svizzera Italiana, Bellinzona, Switzerland; Ospedale Evangelico, Genova, Italy; Istituto Nazionale Tumori, Milano, Italy
| | - F. Ciceri
- Ospedale San Giuseppe, Milano, Italy; Istituto Scientifico San Raffaele, Milano, Italy; Istituto Oncologico Svizzera Italiana, Bellinzona, Switzerland; Ospedale Evangelico, Genova, Italy; Istituto Nazionale Tumori, Milano, Italy
| | - J. Peccatori
- Ospedale San Giuseppe, Milano, Italy; Istituto Scientifico San Raffaele, Milano, Italy; Istituto Oncologico Svizzera Italiana, Bellinzona, Switzerland; Ospedale Evangelico, Genova, Italy; Istituto Nazionale Tumori, Milano, Italy
| |
Collapse
|
5
|
Regola E, Vito G, Croxatto D, Bandettini R, Revello R, Illiberi O, Caliguri P, Dallera M, Pescarollo A, Morelli P, Annovazzi G, Devoto G, Perfumo M, Graziani A, Pescetto L, Usiglio D, Capuzzo R, Battola E, Borreanaz T, Marchese A, Debbia E. DISTRIBUZIONE DELLA SENSIBILITÀ E DELLE CLASSI DI RESISTENZA SIMULTANEA AGLI ANTIBIOTICI IN ESCHERICHIA COLI. Microbiol Med 2007. [DOI: 10.4081/mm.2007.2864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
6
|
Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A, Zoli V, Fornari A, Novero D, Cabras A, Stella M, Comino A, Remotti D, Ponzoni M, Caracciolo D, Ladetto M, Magni M, Devizzi L, Rosato R, Boccadoro M, Bregni M, Corradini P, Gallamini A, Majolino I, Mirto S, Gianni AM. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia 2007; 21:1802-11. [PMID: 17554382 DOI: 10.1038/sj.leu.2404781] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
A prospective multicenter program was performed to evaluate the combination of rituximab and high-dose (hd) sequential chemotherapy delivered with multiple autologous peripheral blood progenitor cell (PBPC) support (R-HDS-maps regimen) in previously untreated patients with diffuse large B-cell lymphoma (DLB-CL) and age-adjusted International Prognostic Score (aaIPI) score 2-3. R-HDS-maps includes: (i) three APO courses; (ii) sequential administration of hd-cyclophosphamide (CY), hd-Ara-C, both supplemented with rituximab, hd-etoposide/cisplatin, PBPC harvests, following hd-CY and hd-Ara-C; (iii) hd-mitoxantrone (hd-Mito)/L-Pam + 2 further rituximab doses; (iv) involved-field radiotherapy. PBPC rescue was scheduled following Ara-C, etoposide/cisplatin and Mito/L-Pam. Between 1999 and 2004, 112 consecutive patients aged <65 years (74 score 2, 38 score 3) entered the study protocol. There were five early and two late toxic deaths. Overall 90 patients (80%) reached clinical remission (CR); at a median 48 months follow-up, 87 (78%) patients are alive, 82 (73%) in continuous CR, with 4 year overall survival (OS) and event-free survival (EFS) projections of 76% (CI 68-85%) and 73% (CI 64-81%), respectively. There were no significant differences in OS and EFS between subgroups with Germinal-Center and Activated B-cell phenotype. Thus, life expectancy of younger patients with aaIPI 2-3 DLB-CL is improved with the early administration of rituximab-supplemented intensive chemotherapy compared with the poor outcome following conventional chemotherapy.
Collapse
Affiliation(s)
- C Tarella
- Dip Medicina-Oncologia Sperimentale, Divisione Universitaria di Ematologia, Torino, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Bregni M, Fleischhauer K, Bernardi M, Pescarollo A, Guggiari E, Lunghi F, Deola S, Scaramuzza S, Re F, Setola E, Monari M, Mazzi B, Servida P, Corradini P, Peccatori J. Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer. Bone Marrow Transplant 2006; 37:311-5. [PMID: 16400340 DOI: 10.1038/sj.bmt.1705248] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We assessed mammaglobin (MMG) gene expression in bone marrow (BM) aspirates from patients with advanced breast cancer who had received a reduced-intensity conditioning and stem cell allografting, in order to detect a graft-versus-tumor effect on micrometastatic disease. Nine patients received a reduced-intensity conditioning with fludarabine, cyclophosphamide, and thiotepa, followed by peripheral blood allografting from HLA-identical sibling donors. Nested RT-PCR analysis with sequence-specific primers for MMG was carried out on a monthly basis on BM samples. Three patients had MMG-positive BM, four patients had MMG-negative BM before allografting, and two were undetermined. In two patients, a clinical response after allografting (partial remission) occurred concurrently with the clearance of MMG expression, at a median of 6 months after allografting, following immune manipulation. In two patients, a prolonged stable disease and negative MMG expression occurred after day +360 from allografting. In two patients, progression of the disease was associated with MMG RT-PCR changing from negative to positive. In one case, a disease response occurring after donor lymphocyte infusion and grade II acute GVHD was heralded by negativization of MMG expression. Although preliminary, these data suggest that a graft-versus-breast cancer effect is detectable on micrometastatic BM disease.
Collapse
Affiliation(s)
- M Bregni
- Division of Hematology-Bone Marrow Transplantation, Department of Oncology, Hematology-Bone Marrow Transplantation Unit, and Blood Bank--Tissue Typing Laboratory, Istituto Scientifico H San Raffaele, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
De Laurenzi A, Iudicone P, Zoli V, De Rosa L, Guglielmetti M, Pescarollo A, Papetti C, Pacilli L, Lapponi P, Petti N. Recombinant interleukin-2 treatment before and after autologous stem cell transplantation in hematologic malignancies: clinical and immunologic effects. J Hematother 1995; 4:113-20. [PMID: 7633841 DOI: 10.1089/scd.1.1995.4.113] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Autologous bone marrow transplantation (ABMT) for hematologic malignancies is associated with a high relapse rate. Interleukin-2 (IL-2) administration is a therapy that may prevent relapse if used when the tumor burden is minimal. In this study we administered recombinant IL-2 (rIL-2) therapy to 12 patients affected by hematologic malignancies either before or after autologous stem cell transplantation (ASCT). rIL-2 was given by a 6 day continuous intravenous infusion with escalating doses, up to 18 x 10(6)/m2/day, depending on patient tolerance. The functional immune responses of the patients were assessed as natural killer (NK) and lymphokine-activated killer (LAK) cytotoxic activities and in vitro interferon-gamma (IFN-gamma) and tumor necrosis factor alpha (TNF-alpha) synthesis. During rIL-2 treatment, the expected side effects occurred; only 3 patients, who showed severe cardiovascular toxicity, required suspension of the treatment. All toxicities reversed after the end of the therapy. Immunologic monitoring was carried out the day before starting rIL-2 infusion and then repeated on days 3, 7, and 14 after rIL-2 was discontinued. Following every rIL-2 course, a pronounced increase in CD3+, CD8+, CD56+ cells was found, with a peak value on day 3. The NK and LAK activities showed a significant increase on day 3 (p < 0.001) over pretherapy values; the increase lasted until day 14, although the difference at later time points was not significant. Before transplant the synthesis of both IFN-gamma and TNF-alpha decreased following rIL-2 therapy, whereas higher levels of these lymphokines were found after posttransplant rIL-2 courses.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
MESH Headings
- Adolescent
- Adult
- Bone Marrow Transplantation
- Child
- Cytotoxicity Tests, Immunologic
- Feasibility Studies
- Female
- Hematopoietic Stem Cell Transplantation
- Hematopoietic Stem Cells/drug effects
- Humans
- Interleukin-2/adverse effects
- Interleukin-2/therapeutic use
- Leukemia/blood
- Leukemia/immunology
- Leukemia/therapy
- Leukemia, Myeloid, Acute/blood
- Leukemia, Myeloid, Acute/immunology
- Leukemia, Myeloid, Acute/therapy
- Lymphoma, Non-Hodgkin/blood
- Lymphoma, Non-Hodgkin/immunology
- Lymphoma, Non-Hodgkin/therapy
- Male
- Middle Aged
- Multiple Myeloma/blood
- Multiple Myeloma/immunology
- Multiple Myeloma/therapy
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy
- Recombinant Fusion Proteins/adverse effects
- Recombinant Fusion Proteins/therapeutic use
- Treatment Outcome
Collapse
Affiliation(s)
- A De Laurenzi
- Department of Haematology, S. Camillo Hospital, Rome, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Del Monte C, Basso P, Consoli P, Cossutta M, Morara R, Pescarollo A, Lanti T. Collection of peripheral blood stem cells by apheresis with continuous flow blood cell separator Dideco Vivacell. Haematologica 1990; 75 Suppl 1:18-21. [PMID: 2351340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
In S. Camillo Hospital, Rome, the Apheresis Center (CNTS-CRI) and the Haematological Division, Authors treated 17 patients affected by haematologic malignances and solid tumours with leukoapheresis procedures for PBSC collection. Nine patients were treated with continuous-flow cell separator Dideco Vivacell, performing a total of 50 collection procedures. Mean values of total collected NC and MNC were 6.5 x 10(9) and 5.5 x 10(9), with a mean recovery 24% and 52%. Authors took patient's blood samples during the procedure, in order to analyze the MNC collection and to optimize the separation efficiency. Haemopoietic reconstitution values of the eight patients submitted to APBSCT showed the effectiveness of our method of cell collection.
Collapse
Affiliation(s)
- C Del Monte
- Servizio Aferesi C.N.T.S.-C.R.I., Roma, Italy
| | | | | | | | | | | | | |
Collapse
|